PolyMedix closes $15M placing

Pennsylvania, USA-based PolyMedix, an emerging biotechnology firm developing acute-care therapeutic drugs for infectious diseases and cardiovascular disorders, has completed a $4.25 million private placement of preferred stock units. Each unit was priced at $7.00 and consisted of one share of PolyMedix convertible preferred stock and a five-year warrant initially exercisable for one share of its convertible preferred stock at $10.00 each. Emerging Growth Equities of King of Prussia, PA, was the placement agent and Carter Securities of New York acted as a selected dealer in the private placement.